Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0144067 |
| CAS No | NA |
| Mol.F. | C16H21N3O |
| Mol.Wt. | 271.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144068 |
| CAS No | NA |
| Mol.F. | C17H19N4O3S : Cl |
| Mol.Wt. | 359.4 : 35.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144069 |
| CAS No | NA |
| Mol.F. | C14H17N3O |
| Mol.Wt. | 243.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144070 |
| CAS No | NA |
| Mol.F. | C17H22N4O3S |
| Mol.Wt. | 362.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144071 |
| CAS No | NA |
| Mol.F. | C17H19N4O3S : Cl |
| Mol.Wt. | 359.4 : 35.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144072 |
| CAS No | NA |
| Mol.F. | C20H31N5O5S2 |
| Mol.Wt. | 485.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144073 |
| CAS No | NA |
| Mol.F. | C20H26N5O5S2 : Cl |
| Mol.Wt. | 480.6 : 35.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144074 |
| CAS No | NA |
| Mol.F. | C17H24N4O4S |
| Mol.Wt. | 380.46 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144075 |
| CAS No | NA |
| Mol.F. | C18H24N4O5S |
| Mol.Wt. | 408.47g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144076 |
| CAS No | NA |
| Mol.F. | C20H26N5O5S2 |
| Mol.Wt. | 480.58 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144077 |
| CAS No | NA |
| Mol.F. | C20H30N4O5S2 |
| Mol.Wt. | 470.60g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144078 |
| CAS No | NA |
| Mol.F. | C20H31N5O5S2 |
| Mol.Wt. | 485.62 /mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144079 |
| CAS No | NA |
| Mol.F. | C17H22N4O3S |
| Mol.Wt. | 362.45 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144080 |
| CAS No | NA |
| Mol.F. | C16H22N4O3S |
| Mol.Wt. | 350.44g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0144081 |
| CAS No | NA |
| Mol.F. | C19H30N4O5S |
| Mol.Wt. | 426.53 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |